Table 1 Characteristics and outcomes of the study population in ICU admission
From: HDL proteome and apolipoproteins concentrations in severe ICU COVID-19 patients
Characterisitics | Study population (n = 37) | Survivors (INC) (n = 18) | Non-survivors (n = 19) | Survivors (INC) vs Non-survivors |
|---|---|---|---|---|
p-values | ||||
Age, years, median [IQR] | 61 [54; 68] | 59 [51; 65] | 61 [57; 68] | 0.3047 (ns) |
Male sex, n (%) | 37 (89%) | 16 (89%) | 17 (89%) | > 0.9999 (ns) |
Obesity | 13 (35%) | 6 (33%) | 7 (37%) | > 0.9999 (ns) |
BMI, kg/m2, median [IQR] | 28 [24; 31] | 26 [24; 30] | 29 [25; 33] | 0.3677 (ns) |
High Blood pressure, n (%) | 15 (41%) | 5 (28%) | 10 (53%) | 0.1837 (ns) |
Diabetes mellitus, n (%) | 13 (35%) | 5 (28%) | 8 (42%) | 0.4951 (ns) |
Timing between fist symptoms and hospitalization (days), median [IQR] | 8 [5; 9] | 8 [5; 11] | 7 [5; 9] | 0.6781 (ns) |
Medication | ||||
Statin, n (%) | 0 | 0 | 0 | > 0.9999 (ns) |
Corticosteroides, n (%) | 0 | 0 | 0 | > 0.9999 (ns) |
Outcomes | ||||
Time between hospitalization and death (days), median [IQR] | 13 [8; 27] | N.A | 13 [8; 27] | N.A |
Clinical features | ||||
TC, mmol/L, median [IQR] | 3.45 [3.09; 3.91] | 3.28 [2.81; 3.62] | 3.62 [3.19; 4.24] | 0.0426 (*) |
HDL-C, mmol/L, median [IQR] | 0.49 [0.40; 0.58] | 0.50 [0.43; 0.58] | 0.48 [0.40; 0.63] | 0.8381 (ns) |
LDL-C, mmol/L, median [IQR] | 1.64 [1.37; 2.15] | 1.98 [1.51; 2.26] | 1.46 [1.34; 2.06] | 0.1100 (ns) |
TG, mmol/L, median [IQR] | 1.74 [1.51; 2.06] | 1.71 [1.52; 2.17] | 1,75 [1.46; 1.95] | 0.0554 (ns) |
CRP, mg/L, mean [± SD] | 136 [± 74.34] | 123 [± 86.37] | 146 [± 66.14] | 0.4976 (ns) |